Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667468 · ClinicalTrials.gov registry record · Phase 2
Cold Stored Platelet in Hemorrhagic Shock
A Phase 2 study, sponsored by Jason Sperry.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT04667468: Completed Phase 2 study, sponsored by Jason Sperry.
NCT04667468 is a Phase 2 study that has completed, run by Jason Sperry. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667468, a Phase 2 study, has completed, sponsored by Jason Sperry.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The Cold Stored Platelet Early Intervention in Hemorrhagic Shock (CriSP-HS) trial is a proposed 3 year, open label, multi-center, randomized trial designed to determine the feasibility, efficacy, and safety of urgent release cold stored platelets (CSP) in patients in hemorrhagic shock. Patients will be randomized to receive either standard care or early infusion of urgent release cold stored platelets (CSP). The proposed pilot study will utilize 5 level-1 trauma centers from within the LITES network and will enroll approximately 200 patients. The primary outcome for the pilot trial is feasibility, with principal secondary clinical outcome of 24 hour mortality.
Primary Outcome
Proportion of eligible patients that can be randomized, enrolled, adhere to protocol, and completed follow-up
Interventions
- BIOLOGICAL Standard Care
- BIOLOGICAL Cold Stored Platelets (CSP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 2 |
What the finished NCT04667468 record still lists
NCT04667468 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT04667468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04667468 about?
NCT04667468 is a clinical study titled "Cold Stored Platelet in Hemorrhagic Shock". The Cold Stored Platelet Early Intervention in Hemorrhagic Shock (CriSP-HS) trial is a proposed 3 year, open label, multi-center, randomized trial designed to determine the feasibility, efficacy, and safety of urgent release cold stored platelets (CSP) in patients in hemorrhagic shock. Patients will...
What is the current status of trial NCT04667468?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-06-21. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT04667468?
The interventions under investigation include: Standard Care (BIOLOGICAL), Cold Stored Platelets (CSP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04667468?
This trial is sponsored by Jason Sperry, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04667468's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI